Compare BMM & EIKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMM | EIKN |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | Canada | United States |
| Employees | 68 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.1M | 631.0M |
| IPO Year | N/A | 2026 |
| Metric | BMM | EIKN |
|---|---|---|
| Price | $4.83 | $7.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $11.81 | ★ $24.60 |
| AVG Volume (30 Days) | 410.8K | ★ 518.4K |
| Earning Date | 11-23-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.47 | $7.55 |
| 52 Week High | $8.63 | $16.50 |
| Indicator | BMM | EIKN |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 35.89 |
| Support Level | $4.81 | N/A |
| Resistance Level | $6.08 | $10.20 |
| Average True Range (ATR) | 0.39 | 0.64 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 8.21 | 12.80 |
Blue Moon Metals Inc is a Canadian exploration stage company focused on the exploration and development of mineral resource properties. The company is advancing its Blue Moon polymetallic deposit which contains zinc, gold, silver, and copper. The projects of the company include the Nussir copper-gold-silver property in Norway (the "Nussir Property"), the Blue Moon zinc-copper-gold-silver property in California, USA (the "Blue Moon Property"), the NSG copper-zinc-gold-silver property in Norway (the "NSG Property") the Springer tungsten-molybdenum project in the Nevada, USA (the "Springer Property") and the Apex germanium-gallium-copper project in Utah, USA (the "APEX Property").
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.